The Effect of Content of Barley Beta-glucans in Bread on Postprandial Blood Sugar
NCT ID: NCT03878576
Last Updated: 2019-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2018-11-26
2018-12-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of Beta-glucan Enriched Barley Flour in Bread on Glycemic Response
NCT02543164
Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
NCT02041104
Effects of Barley on Glucose Control
NCT02367989
Breads Made With Triticum Heritage Varieties: Effect on Post-prandial Glycemia and Insulinemia
NCT03710200
Effects of Bran Size on Glycemic Responses
NCT03314142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
REFERENCE: white bread - BGL0 [RP]
Participants consume a meal of bread BGL0 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
REFERENCE: white bread - BGL0 [RP]
Determination of glycemic response after consumption of BGL0.
TEST: b-glucan enriched bread - BGL2 [IP1]
Participants consume a meal of bread BGL2 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
TEST: b-glucan enriched bread - BGL2 [IP1]
Determination of glycemic response after consumption of BGL0.
TEST: b-glucan enriched bread - BGL3 [IP2]
Participants consume a meal of bread BGL3 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
TEST: b-glucan enriched bread - BGL3 [IP2]
Determination of glycemic response after consumption of BGL0.
TEST: b-glucan enriched bread - BGL4 [IP3]
Participants consume a meal of bread BGL4 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
TEST: b-glucan enriched bread - BGL4 [IP3]
Determination of glycemic response after consumption of BGL0.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
REFERENCE: white bread - BGL0 [RP]
Determination of glycemic response after consumption of BGL0.
TEST: b-glucan enriched bread - BGL2 [IP1]
Determination of glycemic response after consumption of BGL0.
TEST: b-glucan enriched bread - BGL3 [IP2]
Determination of glycemic response after consumption of BGL0.
TEST: b-glucan enriched bread - BGL4 [IP3]
Determination of glycemic response after consumption of BGL0.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged above 18 years at the time of the signature of ICF
* No known food allergy or intolerance
* No medications known to affect glucose tolerance - stable doses of oral contraceptives, acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable.
* Willing to follow all study procedures, including attending all site visits (including sessions for blood sampling and use of CGM)
* Body mass index (BMI) \> 25
Exclusion Criteria
* Aged above 18 years at the time of the signature of ICF
* No known food allergy or intolerance
* No medications known to affect glucose tolerance - stable doses of oral contraceptives, acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable.
* Willing to follow all study procedures, including attending all site visits (including sessions for blood sampling and use of CGM)
* Body mass index (BMI) \> 25
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Community Health Centre Ljubljana
OTHER
Slovenian Research Agency
OTHER
Valens Int. d.o.o., Slovenija
INDUSTRY
Institute of Nutrition, Slovenia (Nutris)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Igor Pravst, PhD
Role: STUDY_CHAIR
Institut za nutricionistiko
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nutrition Institite
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KME/0120-441/2018/4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.